Seizure Disorders · Chapter 1
The Seizure-Disorder Decision Framework
How to prescribe psychotropics when a seizure disorder is in the room — which drugs actually provoke seizures, how antiseizure medications quietly rewrite your drug levels, and when the antiseizure medication is itself the psychiatric problem.
Bottom Line Up Front
The 30-second version
- Psychiatric illness is the rule in epilepsy, not the exception — depression, anxiety, psychosis, and ADHD all run well above general-population rates, and the relationship is bidirectional. "Just don't prescribe" isn't an option; you have to treat through the seizure disorder, safely.
- Three forces govern every psychotropic decision here: (1) does the drug lower the seizure threshold? (2) will an antiseizure medication change the drug's level? (3) is the antiseizure medication itself causing the psychiatric symptom? Miss any one and you get a preventable seizure, a subtherapeutic drug, or a misdiagnosis.
- The provocation danger concentrates in a short list. Bupropion and clozapine lead it; most antipsychotics and TCAs sit lower and dose-dependent; SSRIs and SNRIs are the safe lane. The more common error is the opposite one — reflexively withholding safe, effective antidepressants from a patient who needs them.
- Every antiseizure medication carries the FDA class-wide suicidality warning. Screen for it and counsel on it — but don't let a contested class label frighten you or the patient away from treatment that controls seizures and, often, stabilizes mood.
The Three Questions Before Any Psychotropic
The organ-impairment courses in this series turn on a single axis — how much a failing kidney or liver clears the drug. A seizure disorder is different: it pulls on three independent axes at once, and a safe prescription has to clear all three. Run these before you write anything.
| Question | What you're really asking | Where it's answered |
|---|---|---|
| 1. Does it provoke seizures? | Does this agent lower the seizure threshold enough to matter in someone already predisposed — and is the risk dose-related? | Threshold section below → the Bupropion & Watchlist chapters. |
| 2. Will an ASM move its level? | Is the patient on an enzyme-inducing antiseizure medication that will crush the psychotropic's level — or valproate, which raises some drugs? | Interaction engine below → the Interaction chapters. |
| 3. Is the ASM the culprit? | Could the depression, irritability, or psychosis you're being asked to treat actually be an adverse effect of the antiseizure medication itself? | ASM-as-psychotropic section below → the ASM Psychiatric-Effects chapter. |
This chapter builds the map for all three. The mg thresholds, interaction magnitudes, and titration schedules live in the member chapters — kept out of this free preview on purpose.
Force 1 — The Seizure Threshold: A Provocation Hierarchy
Almost any psychotropic can lower the seizure threshold at a high enough dose or blood level, but the clinically meaningful risk is concentrated in a few agents and is dose-related far more than categorical. The job is not to fear every drug — it's to know the short list at the top of the ladder and to respect dose and titration.
| Tier | Agents (orientation only) |
|---|---|
| Highest concern clear, dose-dependent risk |
Bupropion — the defining seizure-threshold psychotropic: dose-related risk, and contraindicated in a seizure disorder, in bulimia or anorexia nervosa, and during abrupt withdrawal of alcohol, benzodiazepines, barbiturates, or antiseizure medications — the last especially relevant here. Clozapine — dose- and titration-dependent seizure risk that becomes a real prescribing constraint at higher levels. |
| Dose-dependent, use with care | Tricyclic antidepressants (especially at high dose or in overdose), chlorpromazine and other low-potency/sedating antipsychotics, and any agent that accumulates when its metabolism is inhibited. Risk rises with dose, rapid titration, and stacking of threshold-lowering drugs. |
| The safe lane | Most SSRIs and SNRIs carry little meaningful threshold effect at therapeutic doses — they are first-line for depression and anxiety in epilepsy, and controlled data suggest a neutral-to-favorable seizure profile. Observational studies show a small seizure signal, but it is confounded by the depression itself and by overdose; the safe lane is low, not zero — and withholding these agents is the bigger mistake. |
Notice the shape: the danger is a short list, and it is mostly about dose. Get bupropion and clozapine right, respect titration, and avoid stacking, and you have managed most of the provocation risk. The agent-by-agent thresholds are in the Bupropion and Seizure-Threshold Watchlist chapters.
Force 2 — The Interaction Engine: Inducers vs the Inhibitor
This is the force with no parallel in the organ courses, and the one most often missed. Several antiseizure medications are among the most powerful enzyme inducers in all of medicine; one key agent is a potent inhibitor. Either way, the number on the psychotropic's label is not the number in your patient.
| Mechanism | Consequence for your psychotropic |
|---|---|
| Strong inducers carbamazepine, phenytoin, phenobarbital, primidone (oxcarbazepine & topiramate: weaker, dose-dependent) | Induce CYP enzymes, UGTs, and P-glycoprotein — and can drastically lower serum levels of many antidepressants and antipsychotics, driving apparent "treatment resistance" that is really underdosing. Carbamazepine also auto-induces, so its own levels drift over the first weeks. |
| The inhibitor valproate | Inhibits metabolism and glucuronidation — most dangerously, it roughly halves lamotrigine clearance, so lamotrigine levels climb and the risk of a serious rash (Stevens-Johnson spectrum) rises unless the titration is deliberately slowed. |
The practical reflex: before you call a psychotropic a failure in an epilepsy patient, check what antiseizure medication they're on. An inducer may be the reason it "isn't working"; valproate may be the reason a co-prescribed drug is climbing. The quantitative interactions are in the Interaction chapters.
Force 3 — The Antiseizure Medication Is a Psychotropic
Here is the inversion that makes this course different. In the kidney and liver courses, valproate, carbamazepine, and lamotrigine were drugs to dose around. In epilepsy they are drugs the patient is already taking — and they cut both ways.
| The two edges | What it means at the point of care |
|---|---|
| The opportunity | Valproate, carbamazepine, and lamotrigine are also mood stabilizers. When a patient with epilepsy also has bipolar disorder or affective instability, the right ASM can treat both conditions with one drug — lamotrigine in particular for the depressive pole. Choosing the seizure medication is a psychiatric decision. |
| The harm | Some ASMs cause psychiatric illness. Levetiracetam is the classic culprit — irritability, aggression, depression, occasionally psychosis ("the Keppra effect"). Topiramate brings cognitive slowing and depression; phenobarbital and other barbiturates, depression. Before treating the symptom, ask whether the seizure drug is producing it. |
And overlaying all of it: every antiseizure medication carries the FDA class-wide warning for suicidal thoughts and behavior, applied across the class since 2008. The signal is debated — more recent analyses question whether it holds for the newer agents — but the label language, the medication guide, and your obligation to screen and counsel all stand. Full treatment in the ASM Psychiatric-Effects chapter.
Peri-ictal Timing: When the Symptom Happens Tells You What It Is
One organizing idea reframes almost every psychiatric complaint in epilepsy: time the symptom to the seizure. The same presentation means different things — and calls for different action — depending on where it sits relative to ictal activity.
- Pre-ictal — irritability or dysphoria building in the hours before a seizure.
- Ictal / peri-ictal — fear, déjà vu, or altered awareness that is the seizure; treat the epilepsy, not a primary anxiety disorder.
- Postictal — depression and, classically, postictal psychosis emerging after a lucid interval following a cluster of seizures; usually self-limited but high-risk.
- Interictal — the chronic, between-seizure mood, anxiety, and psychotic syndromes that most resemble primary psychiatric illness and that you treat as such.
And the paradox worth knowing by name: forced normalization (the Landolt phenomenon) — psychiatric symptoms, often psychosis, appearing precisely as the seizures come under control and the EEG normalizes. Counterintuitive, easy to misattribute to the psychotropic, and a reminder that seizure control and mental health are not the same axis. The peri-ictal syndromes and their management are the subject of a dedicated chapter; the events that are not seizures at all — psychogenic nonepileptic seizures (PNES) — get their own.
The Undertreatment Trap
The single most common error in this whole domain is not causing a seizure — it's failing to treat psychiatric illness out of misplaced fear. Depression is the most frequent psychiatric comorbidity in epilepsy, it independently worsens quality of life and seizure outcomes, and it is undertreated in part because clinicians overestimate the seizure risk of antidepressants.
The reassurance to carry into the room: most psychotropics are safe in epilepsy when chosen and dosed with the three forces in mind. SSRIs and SNRIs are first-line and carry little meaningful threshold risk at therapeutic doses. The real skill is not blanket avoidance — it's picking the right agent, respecting dose and titration, checking the ASM interactions, and monitoring. That is what the rest of this course teaches, drug by drug.
The Action Ladder
Treating depression or anxiety in a stable epilepsy patient
Reach for an SSRI or SNRI first. Little meaningful threshold effect at therapeutic doses; start low, titrate at a normal pace, and check what antiseizure medication they're on — an inducer may force a higher-than-usual dose.
A threshold-active agent looks clinically necessary
Bupropion, clozapine, a TCA, or a sedating antipsychotic can still be the right drug — but confirm the seizure disorder is controlled, avoid rapid titration, don't stack multiple threshold-lowering drugs, and set a dose ceiling. Bupropion remains contraindicated in an active seizure disorder.
The patient is on an enzyme-inducing ASM
Assume many psychotropic levels are lower than the label predicts. Anticipate needing a higher dose or a non-induced alternative; if valproate is on board, watch for the drugs it raises — lamotrigine above all.
New or worsening psychiatric symptoms after an ASM change
Before adding a psychotropic, ask whether the antiseizure medication is the cause — levetiracetam and topiramate especially — and whether the timing points to a peri-ictal syndrome or forced normalization. The fix may be changing the seizure drug, not starting a new one.
Clinical Pearls
Pearls
- Don't withhold antidepressants. The commonest mistake is undertreating depression in epilepsy out of fear. SSRIs/SNRIs are first-line and low-risk at therapeutic doses.
- Bupropion and clozapine are the two names to memorize. Dose-related seizure risk that genuinely constrains prescribing — bupropion outright contraindicated in a seizure disorder. (Full detail in the Bupropion chapter.)
- Check the ASM before calling a drug a failure. An enzyme-inducing antiseizure medication can crush a psychotropic level into the subtherapeutic range — apparent "resistance" that is really underdosing.
- Valproate + lamotrigine is a rash trap. Valproate roughly halves lamotrigine clearance; the titration must be slowed or you invite a serious hypersensitivity reaction.
- Ask what the antiseizure drug is doing to mood. Levetiracetam irritability/aggression and topiramate cognitive-affective slowing are frequent, reversible, and easy to misdiagnose as primary psychiatric illness.
- Time the symptom to the seizure. Postictal, interictal, and forced-normalization presentations look alike but mean different things and call for different action.
- The suicidality class warning is real on the label and contested in the data. Screen and counsel; don't let it drive undertreatment of either the epilepsy or the mood disorder.
Red Flags — Stop and Reassess
Stop and reassess
- A threshold-lowering psychotropic (bupropion, clozapine, a TCA) being started or pushed upward in a patient whose seizures are not well controlled.
- Two or more threshold-lowering drugs being stacked, or a rapid titration, in someone with a seizure history.
- Bupropion considered in a patient with a seizure disorder, an eating disorder, or abrupt withdrawal of alcohol, benzodiazepines, barbiturates, or an antiseizure medication — each a labeled contraindication.
- New depression, irritability, aggression, or psychosis appearing after an antiseizure medication was started or increased — suspect the ASM before reaching for a psychotropic.
- Emerging psychosis as seizures come under control — consider forced normalization rather than a primary psychotic disorder.
- Any patient with epilepsy expressing suicidal thoughts — the comorbidity and the class warning both raise the baseline; screen actively and connect them with support.
Patient Counseling Script
Plain-language script
"Your seizure condition and your mood are connected, and it's both safe and important to treat both. The medicine I'm recommending was chosen to lift your mood without making seizures more likely — but a few rules matter. Take it exactly as prescribed and don't jump the dose, because with some of these medicines the risk goes up at higher doses. Tell me every other medicine you take, including your seizure medicines, because they can change how much of this drug is actually in your system. And let me know right away if your seizures change, if your mood gets darker, or if you develop a rash — those are the things I want to hear about early, not at your next visit."
EMR / Documentation Template
References
- U.S. Food & Drug Administration. FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications. December 2008 (class labeling implemented 2009).
- Klein P, Devinsky O, French J, et al. Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis. JAMA Neurol. 2021;78(9):1118–1127.
- Wellbutrin XL (bupropion hydrochloride extended-release) Prescribing Information. U.S. FDA — dose-related seizure risk; contraindications in seizure disorder, bulimia/anorexia nervosa, and abrupt sedative/alcohol discontinuation.
- Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–255.
- Johannessen Landmark C, Johannessen SI, Patsalos PN. Pharmacological aspects of antiseizure medications: mechanisms, drug interactions, and therapeutic drug monitoring. Epileptic Disord. 2023 — strong enzyme-inducing ASMs; valproate reduces lamotrigine clearance by ~one-half with hypersensitivity risk.
- Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–481.
- Josephson CB, Jetté N. Psychiatric comorbidities in epilepsy. Int Rev Psychiatry. 2017;29(5):409–424.
- Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336–2344.
- Krishnamoorthy ES, Trimble MR, Sander JWAS, Kanner AM. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002;3(4):303–308.
- Mula M, Kanner AM, Jetté N, Sander JW. Psychiatric comorbidities in people with epilepsy. Neurol Clin Pract. 2021;11(2):e112–e120.
Last reviewed July 2026. Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
You have the framework. Now get the drug-by-drug answers.
This chapter taught you how to weigh the three forces before prescribing. The member chapters give you the dose ceilings, interaction magnitudes, and titration schedules for every agent — starting with the drug everyone asks about first: bupropion.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material.
Responses